Studies presented at MAP2024 showcase the potential of CTCs, exo-miRNA, cfRNA in Cancer Detection and Progression Prediction – ESMO
ESMO – European Society for Medical Oncology shared a post on LinkedIn:
“Three studies presented at MAP2024 showcase the potential of circulating tumour cells (CTCs), exosomal microRNA (exo-miRNA), and cell-free RNA (cfRNA) in Cancer Detection and Progression Prediction.
➡ CTCs in Colorectal Cancer: Significant reductions in CTCs were observed after 3 months of CAPOX treatment in patients with stage III Colorectal Cancer, suggesting CTCs as a valuable prognostic biomarker.
➡ Exo-miRNA in Breast Cancer: developing an exo-miRNA panel shows promise for metastasis prediction, marking an important step in early cancer detection.
➡ cfRNA for Multicancer Detection: Innovative cfRNA-based tests are being developed to identify cancer-specific biomarkers, aiming for early and accurate detection.
Full commentary by Nicola Fusco on the ESMO Daily Reporter.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023